​

Barretina-Ginesta MP, Madariaga A, Barahona Orpinell M, Gallego A, Guerra Alía EM, Matias-Guiu X, Sanchez Heras AB, Casla-Barrio S, Castaño F, Gonzalez Concepción M, Navarro López M, Hierro Racionera C, Ruz Torres M, Gaba García L. Multidisciplinary management of advanced ovarian cancer in Spain: Expert recommendations for achieving maximum survival and improving patient care. Clin Transl Oncol. 2026. doi:10.1007/s12094-026-04467-6

​

Corral Jaime J, de Castro J, Azkarate A, García Ledo G, Calles A, Marsé R, de Freitas Matos Parreira AS, Villamayor J, Gutiérrez-Sainz L, Benítez-Fuentes J, Casado Elía D, Gutiérrez N, Arregui Valles M, Sarró E, López N, Savana Research Group. Real-world insights into stage I–III non-small cell lung cancer in Spain in the pre-immunotherapy era using AI techniques: The IntellyLUNG study. Life. 2026;16:1119. doi:10.3390/life16071119

​​​

​​Mowitz ME, Ayyagari R, Gao W, Zhao J, Mangili A, Sarda SP. Health care burden of bronchopulmonary dysplasia among extremely preterm infants. Front Pediatr. 2019;7:510. doi:10.3389/fped.2019.00510

 

Tantawy AAG, El-Beshlawy A, Marzouk I, Bavdekar A, Qin Y, Mellgard B, Ben Turkia H. Results from a 12-month open-label phase 1/2 study of velaglucerase alfa in children and adolescents with type 3 Gaucher disease. J Inborn Errors Metab Screen. 2018;6:1-5. doi:10.1177/2326409818765564

 

Deegan P, Sasso FD, Giraldo P, Lau H, Panahloo Z, Zimran A. Treatment patterns from 647 patients with Gaucher disease: An analysis from the Gaucher Outcome Survey. Blood Cells Mol Dis. 2018;68:218-225. doi:10.1016/j.bcmd.2016.10.014

 

Lau H, Belmatoug N, Deegan P, Goker-Alpan O, Schwartz IVD, Shankar SP, Panahlooh Z, Zimran A. Reported outcomes of 453 pregnancies in patients with Gaucher disease: An analysis from the Gaucher Outcome Survey. Blood Cells Mol Dis. 2018;68:226-231. doi:10.1016/j.bcmd.2016.10.003

 

Elstein D, Burrow AT, Charrow J, Giraldo P, Mehta A, Pastores GM, Lee H, Mellgard B, Zimran A. Home infusion of intravenous velaglucerase alfa: Experience from pooled clinical studies in 104 patients with type 1 Gaucher disease. Mol Genet Metab. 2017 120:111-115. doi:10.1016/j.ymgme.2016.08.005

​

Smith L, Rhead W, Charrow J, Shankar SP, Bavdekar A, Longo N, Mardach R, Harmatz P, Hangartner T, Hak-Myung Lee, Crombez E, Pastores GM. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase. Mol Genet Metab. 2016;117:164-71. doi:10.1016/j.ymgme.2015.05.012